SECTM1 and central nervous system cancer: The results showed that the expression of SECTM1 in recurrent or secondary gliomas was significantly higher than that in primary gliomas (Table 1, Figure 1A), and the expression of SECTM1 was positively correlated with the malignancy degree of gliomas.